IDYA Options Signal Caution After Earnings Miss

IDEAYA Biosciences heads into the post-earnings week with options traders at their most defensive in months, analysts trimming targets while keeping buy ratings, and a stock down 16% in a month that is still trading at a steep discount to Street consensus.

The clearest signal this week is in options. The put/call ratio has jumped to 0.35, nearly three standard deviations above its 20-day mean of 0.21, the most defensively skewed reading in recent weeks and well outside normal ranges for a name that has historically leaned call-heavy. The move is sharp: the PCR sat at 0.19 as recently as late October, and the shift higher accelerated into and around the earnings date of November 4. That points to a meaningful surge in demand for downside protection, not a gradual drift. Notably, the 52-week high on the PCR is 2.34, so this is not an extreme in absolute terms, but the speed of the move relative to the name's own recent baseline is what stands out.

Short positioning tells a quieter story. At 10.3% of the free float, shorts are present and meaningful, but the trend has been gently lower: shares short have fallen roughly 9% over the past month, from around 10.3 million to just under 9 million. The borrow market is loose, with availability running at over 1,300% of short interest, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow has crept up 25% over the past week to 0.53%, but it remains well below any level that would pressure existing shorts or deter new ones. Taken together, this is a moderately shorted name in a relaxed lending environment, nothing that suggests a squeeze dynamic.

The Street response to what appears to be a data readout has been clustered and constructive in direction, cautious on price. Four analyst updates arrived on November 4. Three firms lowered their targets: RBC Capital cut to $45 from $48 while keeping Outperform, Truist Securities trimmed to $57 from $59 reiterating Buy, and Guggenheim reduced to $52 from $57 maintaining Buy. The outlier was Wedbush, which raised its target to $63 from $60 while holding Outperform. No rating changed direction. The mean target now sits at $51.54 against a price of $31.33, implying roughly 65% upside by the Street's own math. The analyst recommendation factor scores in the 97th percentile, the most bullish structural signal in the dataset. The bear case is straightforward: IDEAYA is loss-making, with diluted EPS losses of up to $(4.66) and operating losses in the hundreds of millions. Its P/B multiple has contracted 0.53 over the past 30 days to 3.3x, tracking the share price lower. The bull case rests on the DLL3 franchise showing 73% objective response rate and 6.7 months median progression-free survival in second-line-plus small cell lung cancer, a planned Phase 3 monotherapy study by year-end 2026, and a cash position of around $1.3 billion following a $345 million offering.

Ownership is concentrated in long-only funds that have been adding. FMR holds 14.6% and added nearly 933,000 shares in the most recent quarter. BlackRock and State Street both added in the September quarter. Janus Henderson, with 8.9%, added over 1.3 million shares at a prior period. Baker Bros., the specialist healthcare fund, holds 5.2% after adding more than 1 million shares. The institutional picture is one of active managers building positions across multiple quarters, not trimming. On the activist register there are no 13D filers, only passive 13G holders, so no campaign risk. Point72 did reduce from 5% to 2.1% as of its February 2026 disclosure, a notable exit from above the reporting threshold, though stakes are as last disclosed around the 5% threshold and positions may have changed since.

The closest correlated peer, RCUS, gained 4.2% on the week while IDYA fell 6.5%. IMMX was up 6.2% on the day but also down 4.2% on the week. The divergence suggests the pressure on IDYA this week is name-specific rather than a broad biotech rotation.

Wikipedia views for IDEAYA registered a z-score of 5.68 against its own 90-day history as of mid-October, an unusually high spike in retail attention. The dataset is an attention signal only, with no measured link to the company's reported financials.

The next earnings event is scheduled for February 12, 2027. Between now and then, the announced Phase 3 study timeline and any 2H26 data readouts across the DLL3 and darovasertib programs are what the market will be watching to determine whether the gap between the $31 share price and the $51 analyst mean closes or widens further.